Intarcia Therapeutics and pharmaceuticals maker Numab said today that they’ve logged several milestones in their joint project to develop a drug-device combination for treating inflammatory and autoimmune diseases. Wädenswil, Switzerland-based Numab identified a pair of antibody-based compounds for the program, which aims to use the delivery and formulation technology developed by Cambridge, Mass.-based Intarcia. The companies said […]
Intarcia Therapeutics said today that it raised another $75 million in a debt financing round and touted the top-line cardiovascular safety data from the final phase in its clinical program for its ITCA 650 implantable drug pump for Type II diabetics. Boston-based Intarcia said it plans to begin filing for U.S. approval from the FDA during the 3rd […]
Intarcia Therapeutics said today it acquired former GlaxoSmithKline enteroendocrine discovery performance unit Phoundry Pharma for an undisclosed amount. Intarcia said Phoundry’s portfolio of optimized peptides, specifically those focused on diabetes and obesity, would enhance its investigational ITCA 650 miniature osmotic pump for treating diabetes. The device is currently in phase 3 trials. “Incredible progress with ITCA […]
Intarcia Therapeutics yesterday unveiled top-line results from a year-long trial of an implantable drug pump for Type II diabetics, saying its ITCA 650 treatment proved superior to its comparator, Merck‘s (NYSE:MRK) Januvia. Fifty-two week results from the Phase III Freedom-2 trial met all primary and secondary endpoints, “demonstrating superiority over Januvia at every measured time point,” Intarcia said. The matchstick-sized, miniature […]
Medtronic (NYSE:MDT) and Intarcia Therapeutics were in the spotlight at the American Diabetes Assn.’s annual scientific sessions conference in Boston last week, revealing new medical device developments in the fight against diabetes. Medtronic took center stage, announcing new developments for its artificial pancreas program, touting positive data from a user study of its MiniMed 640g and revealing plans to collaborate […]
Intarcia Therapeutics yesterday took its total raise to more than $1 billion with a $225 million funding round it plans to use to run clinical trials and commercialize its the drug-device combination treatment it’s developing for Type II diabetes.
Intarcia Therapeutics said today that French pharmaceutical independent Servier agreed to a deal to commercialize Intarcia’s implantable diabetes pump that could be worth some $1 billion.
Intarcia Therapeutics said it’s reeled in financing worth a total of $210 million to further its drug-device combination treatment for Type II diabetes.
The Hayward, Calif.-based company, which is moving its headquarters to Boston, said the cash will also help facilitate the move.